These additions to the Board auger well for Gensci:
TORONTO, April 15 /CNW/ - GenSci Regeneration Sciences Inc.
Trading Symbol: GNS on The Toronto Stock Exchange
GenSci Regeneration Sciences Inc. today announced the appointments of
Frank M. Clark and Peter van der Velden to its Board of Directors.
''As GenSci continues growing both through the development and
commercialization of our own technologies and products, and by licensing and
alliances with other companies,'' said Dr. James Trotman, Chairman and Chief
Executive Officer, ''the experienced counsel of individuals such as Mr. Clark
and Mr. van der Velden will prove very valuable. We are fortunate to have
been able to attract these individuals to our Board.''
Mr. Clark, who lives in Sarasota, Florida, is a former officer and
director of several Fortune 500 health care companies and is currently
President and Chief Executive Officer of Surgical Safety Products, Inc.
Among the positions held by Mr. Clark in his lengthy career in the health
care industry are Executive Vice-President and a director of Johnson &
Johnson's (J&J) medical electronics ventures, a manufacturer and marketer of
cardiac pacemakers and trans electrical nerve stimulators; Vice-President and
director of Ethicon, a J&J wound closure company; and founder, Vice President
and General Manager of Ethnor Medical, a division of Ethicon. He has also
held a number of other senior positions with, and has participated on the
Boards of, various companies in the health care industry.
Mr. van der Velden, who is based in Toronto, has extensive experience in
the merchant banking, venture capital, and health care sectors. Currently,
Mr. van der Velden is Vice-President and a Managing Director of Bedford
Capital Corporation, a Canadian merchant bank. Previously, he served as
Vice-President, Business Development for Hyal Pharmaceuticals Ltd.,
responsible for all licensing and business development activities. Mr. van
der Velden is a director of three other companies.
GenSci Regeneration Sciences Inc. is an orthobiologics company, focusing
on treatments for musculoskeletal repair, reconstruction, and regeneration.
This biotechnology sector is one of the fastest-growing areas in orthopedics.
The company is currently producing and marketing a proprietary line of
bioimplant products for surgical applications from its Irvine, California
operations. The company's head office and research facilities are located in
the greater Toronto area.
Happy investing,
andras |
